Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
FENOFIBRATE
BGP PHARMA ULC
C10AB05
FENOFIBRATE
160MG
TABLET
FENOFIBRATE 160MG
ORAL
30
Prescription
FRIBIC ACID DERIVATIVES
Active ingredient group (AIG) number: 0118895004; AHFS:
APPROVED
2000-03-02
_Lipidil Supra_ ® _ Product Monograph _ _Page 1 of 40 _ _Date of Revision: January 13, 2017 and Control No. 198973 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR LIPIDIL SUPRA ® fenofibrate, microcoated formulation film-coated tablets (160 mg) LIPID METABOLISM REGULATOR BGP Pharma ULC 85 Advance Road Etobicoke, Ontario M8Z 2S6 Date of Revision: January 13, 2017 Submission Control No.: 198973 ® Lipidil Supra: Registered Trademark Fournier Industrie et Santé, Suresnes, France; Licensed use by BGP Pharma ULC, Etobicoke, Ontario, M8Z 2S6 _Lipidil Supra_ ® _ Product Monograph _ _Page 2 of 40 _ _Date of Revision: January 13, 2017 and Control No. 198973 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 9 DRUG INTERACTIONS ................................................................................................. 13 DOSAGE AND ADMINISTRATION ............................................................................. 18 OVERDOSAGE ............................................................................................................... 19 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 19 STORAGE AND STABILITY ......................................................................................... 20 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 20 PART II: SCIENTIFIC INFORMATION ......... Izlasiet visu dokumentu